gilead

From 10,000 To 3.25 Lakh Vials a Day, How India Solved Remdesivir Crisis

Gilead Announces Steps to Expand Availability of Remdesivir in India

WHO Advises Against Remdesivir to Treat Covid-19 Patients, Says No Proof It Improves Survival Rate

WHO-led Covid Drug Scheme Doubles Down on Antibodies & Steroids, Shuns Remdesivir

Gilead Sciences Nears Deal to Buy Immunomedics for More Than $20 Billion, Says Report

Gilead Sciences Raises 2020 Sales Outlook to Include Covid-19 Treatment Remdesivir

Jubilant Life Sciences Gets DCGI Nod For Generic Version of Covid-19 Drug

UK Emergency Remdesivir Supplies Adequate to Treat Coronavirus, Says Official

British Experts Slam US for Hoarding Global Supply of Covid-19 Drug Remdesivir

South Korea Backs Remdesivir for Covid-19 Treatment, Urges Caution with Dexamethasone

Gilead's Anti-viral Drug Remdesivir Endorsed as First Coronavirus Treatment in Europe

Gilead to Buy 49.9% Stake in Cancer Drug Developer Pionyr for $275 Million

Gilead Targets Remdesivir Supply for Two Million Covid-19 Patients By Year-end

Covid-19 Pandemic: India's Zydus Cadila Signs Pact with Gilead Sciences to Make Antiviral Drug Remdesivir

AstraZeneca Shares Down 2% After Report it Approached Gilead Over Tie-up

AstraZeneca Approaches Rival Drugmaker Gilead about Potential Merger: Report

Roche Mixes Actemra With Gilead's Remdesivir in Covid-19 Trial

Gilead to End Coronavirus Drug Trials, Adding to Access Worry: Researchers

Health Groups Ask India to Rescind Gilead's Patents for Covid-19 Drug Remdesivir

Health Groups Ask India to Rescind Gilead's Patents for Covid-19 Drug Remdesivir